Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

Douglas A. Schow, Leonard G. Renfer, Thomas A Rozanski, Ian M. Thompson

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objectives. We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy. Methods. Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes. Results. Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20%; in 69%, hot flushes were noted during treatment but resolved after termination of treatment; and in 11%, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes. Conclusions. Hot flushes will be noted in 80% of patients who receive neoadjuvant hormonal therapy. In approximately 10%, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.

Original languageEnglish (US)
Pages (from-to)855-857
Number of pages3
JournalSouthern Medical Journal
Volume91
Issue number9
StatePublished - Sep 1998

Fingerprint

Neoadjuvant Therapy
Prostatic Neoplasms
Therapeutics
Prostatectomy
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schow, D. A., Renfer, L. G., Rozanski, T. A., & Thompson, I. M. (1998). Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. Southern Medical Journal, 91(9), 855-857.

Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. / Schow, Douglas A.; Renfer, Leonard G.; Rozanski, Thomas A; Thompson, Ian M.

In: Southern Medical Journal, Vol. 91, No. 9, 09.1998, p. 855-857.

Research output: Contribution to journalArticle

Schow, DA, Renfer, LG, Rozanski, TA & Thompson, IM 1998, 'Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer', Southern Medical Journal, vol. 91, no. 9, pp. 855-857.
Schow, Douglas A. ; Renfer, Leonard G. ; Rozanski, Thomas A ; Thompson, Ian M. / Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. In: Southern Medical Journal. 1998 ; Vol. 91, No. 9. pp. 855-857.
@article{722a14d997294ddc9a7dd17825b8987d,
title = "Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer",
abstract = "Objectives. We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy. Methods. Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes. Results. Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20{\%}; in 69{\%}, hot flushes were noted during treatment but resolved after termination of treatment; and in 11{\%}, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes. Conclusions. Hot flushes will be noted in 80{\%} of patients who receive neoadjuvant hormonal therapy. In approximately 10{\%}, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.",
author = "Schow, {Douglas A.} and Renfer, {Leonard G.} and Rozanski, {Thomas A} and Thompson, {Ian M.}",
year = "1998",
month = "9",
language = "English (US)",
volume = "91",
pages = "855--857",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

AU - Schow, Douglas A.

AU - Renfer, Leonard G.

AU - Rozanski, Thomas A

AU - Thompson, Ian M.

PY - 1998/9

Y1 - 1998/9

N2 - Objectives. We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy. Methods. Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes. Results. Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20%; in 69%, hot flushes were noted during treatment but resolved after termination of treatment; and in 11%, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes. Conclusions. Hot flushes will be noted in 80% of patients who receive neoadjuvant hormonal therapy. In approximately 10%, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.

AB - Objectives. We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy. Methods. Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes. Results. Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20%; in 69%, hot flushes were noted during treatment but resolved after termination of treatment; and in 11%, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes. Conclusions. Hot flushes will be noted in 80% of patients who receive neoadjuvant hormonal therapy. In approximately 10%, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.

UR - http://www.scopus.com/inward/record.url?scp=0031669857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031669857&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 855

EP - 857

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 9

ER -